ES2296872T3 - Peptidos derivados de tnf para uso en el tratamiento de edema. - Google Patents

Peptidos derivados de tnf para uso en el tratamiento de edema. Download PDF

Info

Publication number
ES2296872T3
ES2296872T3 ES02077256T ES02077256T ES2296872T3 ES 2296872 T3 ES2296872 T3 ES 2296872T3 ES 02077256 T ES02077256 T ES 02077256T ES 02077256 T ES02077256 T ES 02077256T ES 2296872 T3 ES2296872 T3 ES 2296872T3
Authority
ES
Spain
Prior art keywords
tnf
peptide
baselineskip
amino acids
peptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02077256T
Other languages
English (en)
Spanish (es)
Inventor
Patrick De Baetselier
Rudolf Lucas
Jerome Pugin
Alain Bloc
Lucie Fransen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2296872T3 publication Critical patent/ES2296872T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES02077256T 1998-08-14 1999-08-10 Peptidos derivados de tnf para uso en el tratamiento de edema. Expired - Lifetime ES2296872T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP98870180 1998-08-14
EP98870180 1998-08-14
EP98870198 1998-09-18
EP98870198 1998-09-18
EP98870222 1998-10-21
EP98870222 1998-10-21

Publications (1)

Publication Number Publication Date
ES2296872T3 true ES2296872T3 (es) 2008-05-01

Family

ID=27239778

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02077256T Expired - Lifetime ES2296872T3 (es) 1998-08-14 1999-08-10 Peptidos derivados de tnf para uso en el tratamiento de edema.

Country Status (20)

Country Link
US (2) US20030105021A1 (enExample)
EP (3) EP1105152A1 (enExample)
JP (1) JP4542266B2 (enExample)
CN (1) CN1181886C (enExample)
AT (2) ATE395072T1 (enExample)
AU (1) AU764992B2 (enExample)
BR (1) BR9912899A (enExample)
CA (1) CA2334941C (enExample)
CZ (1) CZ302862B6 (enExample)
DE (2) DE69938743D1 (enExample)
DK (1) DK1264599T3 (enExample)
ES (1) ES2296872T3 (enExample)
HU (1) HU227661B1 (enExample)
IL (2) IL141064A0 (enExample)
NZ (1) NZ509604A (enExample)
PL (1) PL203706B1 (enExample)
PT (1) PT1264599E (enExample)
TR (1) TR200100338T2 (enExample)
WO (1) WO2000009149A1 (enExample)
ZA (1) ZA200100656B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227661B1 (hu) 1998-08-14 2011-10-28 Rudolf Lucas Dr TNF-eredetû peptidek ödéma kezelésére
CA2575513C (en) * 2004-08-06 2014-09-16 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506151B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
DK2397151T3 (en) 2010-06-21 2015-05-18 Apeptico Forschung & Entwicklung Gmbh The treatment of the vascular complications of diabetes
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
CN105188735A (zh) * 2013-04-23 2015-12-23 阿佩普蒂科研究和开发有限责任公司 包含式x1-gqretpegaeakpwy-x2的环肽的药物组合物及其体外处理肺的用途
CA2940351A1 (en) 2014-03-18 2015-09-24 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
CN110613838A (zh) * 2018-06-19 2019-12-27 姜石松 增强细胞通透性的多肽及其应用
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
IL294894A (en) 2020-05-08 2022-09-01 Apeptico Forschung & Entwicklung Gmbh A peptide for the prevention or treatment of covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
DE3841759A1 (de) 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
US5891679A (en) 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
HU227661B1 (hu) 1998-08-14 2011-10-28 Rudolf Lucas Dr TNF-eredetû peptidek ödéma kezelésére

Also Published As

Publication number Publication date
CZ2001538A3 (cs) 2001-08-15
HK1051805A1 (en) 2003-08-22
CN1181886C (zh) 2004-12-29
EP1105152A1 (en) 2001-06-13
EP1264599A1 (en) 2002-12-11
US20030185791A1 (en) 2003-10-02
HUP0103117A3 (en) 2004-03-01
DK1264599T3 (da) 2008-02-04
WO2000009149A1 (en) 2000-02-24
DE69937206D1 (de) 2007-11-08
IL141064A (en) 2009-09-01
EP1247531B1 (en) 2008-05-14
PL345997A1 (en) 2002-01-14
ATE374039T1 (de) 2007-10-15
US7258861B2 (en) 2007-08-21
ZA200100656B (en) 2005-06-29
HU227661B1 (hu) 2011-10-28
ATE395072T1 (de) 2008-05-15
JP4542266B2 (ja) 2010-09-08
EP1264599B1 (en) 2007-09-26
BR9912899A (pt) 2001-05-08
CA2334941C (en) 2011-08-09
PL203706B1 (pl) 2009-11-30
NZ509604A (en) 2003-05-30
JP2002522508A (ja) 2002-07-23
AU5620999A (en) 2000-03-06
TR200100338T2 (tr) 2001-12-21
EP1247531A3 (en) 2002-12-18
IL141064A0 (en) 2002-02-10
CZ302862B6 (cs) 2011-12-21
DE69937206T2 (de) 2008-06-19
EP1247531A2 (en) 2002-10-09
DE69938743D1 (de) 2008-06-26
CA2334941A1 (en) 2000-02-24
HUP0103117A2 (hu) 2001-12-28
US20030105021A1 (en) 2003-06-05
AU764992B2 (en) 2003-09-04
PT1264599E (pt) 2008-01-07
CN1312724A (zh) 2001-09-12

Similar Documents

Publication Publication Date Title
JP4542266B2 (ja) 浮腫の治療に使用されるｔｎｆ由来のペプチド
KR100725199B1 (ko) 에이치지에프유전자를함유하는약제
US20080095758A1 (en) Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
ITRM970796A1 (it) Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
CN103038253A (zh) 作为用来稳定生物屏障的活性剂的肽
US9139615B2 (en) High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
Vasquez et al. Replication-Deficient Adenovirus Vector Transfer ofgfpReporter Gene into Supraoptic Nucleus and Subfornical Organ Neurons
ES2286644T3 (es) Compuestos destinados al tratamiento de enfermedades coronarias y/o vasculares perifericas.
PT90118B (pt) Processo para a preparacao de novos polipeptidos exibindo actividade de factor de crescimento e de sequencias de acidos nucleicos que codificam esses polipeptidos
HK1051805B (en) Tnf-derived peptides for use in treating oedema
HK1051802A (en) Tnf-derived peptides for use in treating oedema
US8372799B2 (en) Reverse protein
PT704219E (pt) Utilizacao de um factor proliferativo osteoblastico
MXPA01001527A (en) Tnf-derived peptides for use in treating oedema
KR20010102932A (ko) 안지오포이에틴-1을 포함하는 제약 조성물 및 그의 용도
KR101950502B1 (ko) 호흡기 염증을 현저히 줄이는 펩타이드 및 이를 포함하는 조성물
KR102702011B1 (ko) 폐내 염증의 완화
JPH083065A (ja) 肝臓障害に対する治療剤
WO2007054600A2 (es) Combinación de glicoisoformas para el tratamiento o prevención de la septicemia, línea celular transgénica productora de glicoformas de eritropoyetina, composición farmacéutica que comprende a dicha combinación
JP2020026397A (ja) ＴｒｋＢアンタゴニストを含む医薬組成物
HK1136211B (en) Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage